Skip to content

0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients

0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02595606
Enrollment
60
Registered
2015-11-03
Start date
2015-09-30
Completion date
2016-03-31
Last updated
2016-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Dry Eye Syndromes

Keywords

dry eye syndromes, diabetes mellitus

Brief summary

A randomized parallel controlled study was designed to compare the efficacy of 0.3% Sodium Hyaluronate in the treatment of Dry Eye of diabetic patients.

Interventions

DRUG0.3% Sodium Hyaluronate

five times per day for the intervention of eye drop

Sponsors

Sun Yat-sen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
17 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. medical history of diabetes 2. diagnosed with proliferative diabetic retinopathy 3. diagnosed with dry eye 4. not involvement in other drug experiment in the past 2 weeks 5. vision acuity better than 0.1 6. no local drug using history or with at least 2 weeks blanking period

Exclusion criteria

1. allergy to any of the drug ingredient 2. being or going to be pregnant or in lactation period 3. with any other eye disease or other serious disease which might affect the trial or could not get in follow-up 4. with any eye surgery history in the past six months 5. usage of hormone for replacement therapy

Design outcomes

Primary

MeasureTime frameDescription
ocular surface disease indexup to 2 monthspre-,1,4,8 weeks after the initiation of the study(the use of drug for experimental group)

Secondary

MeasureTime frameDescription
tear break up timeup to 2 monthsBUT
Schirmer' testup to 2 monthstest of tear secretion
conjunctival goblet cells densityup to 2 monthsindirect assessment of tear quality
corneal fluorescein staining assessmentup to 2 monthsassessment of the corneal invasion

Countries

China

Contacts

Primary ContactZhang Xiulan, M.D.
zhangxl2@mail.sysu.edu.cn02087335367

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026